At a glance
Health benefit costs
Exhibit 12027 US employer health cost forecasts
Projected increase
The category on a page
Exhibit 2Where benefits sit
Profit impact against supply risk, HR subcategories
Exhibit 3US health cost growth by year (Marsh)
Total health benefit cost per employee
Typical savings vs unmanaged renewal
Avoided cost increase
Value levers
In order of value.
Get the claims data; challenge insurer trend assumptions.
Market the policy every 2-3 years; fixed broker fees.
Specialist programmes for cancer, cardiac and musculoskeletal care.
Decide coverage rules and pharmacy contracts for obesity drugs.
Flex plans and preventive care reduce claims growth.
How to buy it
KPIs to track
For the monthly review
Where most buyers are, and what good looks like
| Most buyers today | Best practice | ||
|---|---|---|---|
| Data | Premium only | → | Full claims analytics |
| Renewal | Accept insurer offer | → | Negotiate on data; tender regularly |
| Broker | Commission | → | Fixed fee, disclosed |
| Programmes | Generic | → | Targeted at high-cost conditions |
| Design | Same for all | → | Flexible benefits |
What AI changes
More in the AI disruption tab.
Full written analysis
Written live for Benefits and your region, grounded on the figures above. Public data only.
Written live for this category and region when the page opens in a browser.
Negotiation playbook
Negotiation playbook
Insurers price on trend; your leverage is claims data, competition and plan design.
Pick the right commercial model
| Self-funded with stop-lossUsual best | Pay actual claims; best for large groups. |
| Fully insured | Predictable premium; insurer keeps margin. |
| Multi-year rate guarantee | Caps renewals; useful in high inflation. |
| Outcome-based vendor fees | Specialist programmes paid on savings. |
Questions to ask suppliers
- Rate guarantee
Will you cap our renewal increase for two years, and at what level?
Good answer: cap on renewal for 2 years. - Claims data
Will you share full claims data monthly, at member-level detail where the law allows?
Good answer: monthly, full detail. - Performance guarantees
What service and claims standards will you guarantee, with penalties if you miss them?
Good answer: service and claims standards. - Broker fee
What is the broker's total income from our account, including commissions, and will the fee be fixed?
Good answer: fixed and disclosed. - Wellness funds
How much will you fund for wellness programmes each year?
Good answer: insurer-funded programmes.
Your leverage
- Group size
- Claims experience
- Tender competition
- Plan design changes
Watch out for
- Trend assumptions above market
- Hidden broker commissions
- Benefit cuts that hurt retention
AI disruption
Tailwinds for buyers
- Claims analytics find savings.
- Care navigation lowers costs.
- Fraud detection.
- AI plan design modelling shows cost of options before renewal.
- Digital health tools reduce some claim costs.
- Chatbots cut benefit admin costs.
Headwinds for buyers
- New expensive therapies (e.g. GLP-1s) raise costs.
- Insurers use AI to deny or delay claims.
- Health data privacy risks.
- Specialty drug pipelines keep raising trend.
- Vendors sell AI point solutions with unproven savings.
- Employee data sharing raises consent issues.
How to capture it
Insist on claims data access and use analytics before every renewal.
Who is changing the market
- Publishes health cost trend and benefits surveys used in renewals
- Benchmark data helps challenge insurer increases
- Medical trend and analytics data used to set budgets
- Broker analytics show where claims costs come from
- Digital group health insurance for small and mid-sized firms
- Online quotes and claims make prices more transparent
Risk radar
Risk radar
Exposure by dimension, 0-100, Global
Risk heat map
Impact against likelihood; numbers match the register below
- GLP-1 and specialty drug costs
- Double-digit renewals
- High-cost claimants
- Poor claims data
- Employee dissatisfaction
- Health data privacy
Risk register
New therapies drive large claim increases.
US forecasts 8-11%; India ~10%.
Cancer, cardiac and specialty drugs.
Employers can't explain cost increases.
Cost shifting to employees.
Claims data is sensitive personal data.
Market pulse
What the biggest suppliers are reporting
From their latest results and investor material.
2026 National Survey of Employer-Sponsored Health Plans; 1,800+ employers.
2027 trend forecasts; employers paid ~82% of plan costs in 2026.
Q3 2026. Commercial cost trend above its initial 11% view; specialty drugs and billing intensity.
Q3. Moving to a rebate-free PBM model from 2027 for fully insured lives.
FY2026 (Aug). Pricing about +2.4%; FM services +2.9%; North America -1.0%, Europe +2.1%; FY27 guide 2-3%.
Latest developments
Dated, newest first. Checked 16 Nov 2026.
Margins improved through plan design and pricing, not lower use of care.
So what: Expect insurers to push price and plan changes at renewal.
Healthcare Finance News →Highest since 2003; 59% of employers plan cuts.
So what: Start renewal negotiations early with data.
Marsh →Fourth year of near double-digit growth.
So what: Budget for ~9-10% before action.
Managed Healthcare Executive →Down from 11.5%; still above inflation.
So what: Push renewals toward 10% or below.
Deccan Chronicle →What this means for your next negotiation
- Budget 8-10% for 2027 health costs before action; insurers' own trends are above 11%.
- Get claims data first; insurers are improving margins through pricing.
- Target specialty drugs (incl. GLP-1s) and high-cost claimants specifically.
Signals to watch next quarter
Shows employer renewal pressure.
May change pharmacy pricing.
Medical trend ~10%.
Sources
- Marsh National Survey of Employer-Sponsored Health Plans 2026 · Aug 2026
- Aon US 2027 projection · Aug 2026
- Aon 2027 Global Medical Trend Rates, India · 2026
Figures checked 16 Nov 2026. Tags: Official = published by the source; Derived = calculated from published figures; Judgement = The Procurement Lens view.